PRIOLO, GIULIA
 Distribuzione geografica
Continente #
AS - Asia 128
EU - Europa 58
NA - Nord America 46
SA - Sud America 5
AF - Africa 2
Totale 239
Nazione #
US - Stati Uniti d'America 46
IT - Italia 38
SG - Singapore 34
CN - Cina 32
VN - Vietnam 26
HK - Hong Kong 11
KR - Corea 7
GB - Regno Unito 5
IN - India 4
NL - Olanda 4
BR - Brasile 3
ES - Italia 3
JP - Giappone 3
TR - Turchia 3
DE - Germania 2
EC - Ecuador 2
FR - Francia 2
PH - Filippine 2
PL - Polonia 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
IR - Iran 1
MZ - Mozambico 1
Totale 239
Città #
Singapore 24
Hefei 18
Hong Kong 10
Santa Clara 10
Ashburn 7
Ho Chi Minh City 7
Milan 7
Seoul 7
Hanoi 6
Bologna 5
San Jose 5
Acerra 3
Bari 3
Tokyo 3
Biên Hòa 2
Boardman 2
Genoa 2
Istanbul 2
Kolkata 2
Los Angeles 2
Madrid 2
New York 2
Turin 2
Abidjan 1
Al Ain City 1
Baku 1
Bangkok 1
Barcelona 1
Beijing 1
Bengaluru 1
Boston 1
Buffalo 1
Cagliari 1
Caloocan City 1
Chicago 1
Dallas 1
Falconara Marittima 1
Groningen 1
Guangzhou 1
Guayaquil 1
Hải Dương 1
Lauterbourg 1
Lohogaon 1
Maputo 1
Memphis 1
Minneapolis 1
Ninh Bình 1
Nuremberg 1
Phoenix 1
Phuket 1
Piscataway 1
Poplar 1
Quezon City 1
Rome 1
San Francisco 1
Schiffdorf 1
Shanghai 1
Shijiazhuang 1
Sofia 1
São Paulo 1
Tampa 1
Thái Bình 1
Tianjin 1
Tân Tiến 1
Weifang 1
Totale 175
Nome #
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 174
Physical exercise is confirmed to reduce low back pain symptoms in office workers: A systematic review of the evidence to improve best practices in the workplace 67
Totale 241
Categoria #
all - tutte 631
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 631


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20238 0 0 0 0 0 0 0 0 0 1 1 6
2023/202417 0 0 3 4 4 1 2 1 0 0 0 2
2024/202576 5 10 1 7 16 4 4 1 4 4 5 15
2025/2026140 10 20 12 14 10 8 6 7 34 6 7 6
Totale 241